
Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 29 September 2022SV NewsDDF recognizes that the latest lecanemab results represent major progress in the development of new treatments for Alzheimer’s disease.
- 29 September 2022Portfolio NewsPrilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer
- 21 September 2022Portfolio NewsCumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer
- 20 September 2022Portfolio NewsPionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159
- 15 September 2022Portfolio NewsZerigo Health Announces Release of Eczema Solution
- 12 September 2022Portfolio NewsNimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
- 12 September 2022Portfolio NewsAviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner
- 12 September 2022Portfolio NewsAlchemab Therapeutics— Cracking the secrets of protective auto-immunity
- 8 September 2022Portfolio NewsArtemis Health and Zerigo Health Announce Partnership to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditions
- 7 September 2022Portfolio NewsNitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology
- 6 September 2022Portfolio NewsFirst Randomized Controlled Study with RejuvenAir® for Chronic Bronchitis shows Clinically Significant Results
- 26 August 2022Portfolio NewsImbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022